ReviewMutation research2014
The strategies to control prostate cancer by chemoprevention approaches.
Review in Mutation research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Chemotherapeutic Potential of Saikosaponin D: Experimental Evidence.Journal of xenobiotics · 2022Review
- Root Extract of a MicropropagatedEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Leelamine suppresses cMyc expression in prostate cancer cellsJournal of cancer metastasis and treatment · 2021Article
- Grape Powder Supplementation Attenuates Prostate Neoplasia Associated with Pten Haploinsufficiency in Mice Fed High-Fat Diet.Molecular nutrition & food research · 2020Article
- Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3', 5'-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells.International journal of molecular sciences · 2020Article
- Differential effect of grape seed extract and its active constituent procyanidin B2 3,3″-di-O-gallate against prostate cancer stem cells.Molecular carcinogenesis · 2019Article
- Review
- Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.NPJ precision oncology · 2018Review
- Procyanidin B2 3,3″-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.Molecular carcinogenesis · 2018Article
- Fatty Acid Synthesis Intermediates Represent Novel Noninvasive Biomarkers of Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate.Cancer prevention research (Philadelphia, Pa.) · 2017Article
- Masquelier's grape seed extract: from basic flavonoid research to a well-characterized food supplement with health benefits.Nutrition journal · 2017Review
- Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.The American journal of Chinese medicine · 2017Article
- A Review of the Potential of Phytochemicals fromEvidence-based complementary and alternative medicine : eCAM · 2017Review
- A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.Molecules (Basel, Switzerland) · 2016Article
- Suppression of β-catenin Signaling Pathway in Human Prostate Cancer PC3 Cells by Delphinidin.Journal of cancer prevention · 2016Article
- Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment.Life sciences · 2016Review
- Chemoprevention of Low-Molecular-Weight Citrus Pectin (LCP) in Gastrointestinal Cancer Cells.International journal of biological sciences · 2016Article
- Chemoprevention of cancer: current evidence and future prospects.F1000Research · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Prostate cancer (PCA) is the most commonly diagnosed cancer in men in the United States with growing worldwide incidence. Despite intensive investment in improving early detection, PCA often escapes timely detection and mortality remains high; this malignancy being the second highest cancer-associated mortality in American men. Collectively, health care costs of PCA results in an immense financial burden that is only expected to grow. Additionally, even in cases of successful treatment, PCA is associated with long-term and pervasive effects on patients. A proactive alternative to treat PCA is to prevent its occurrence and progression prior to symptomatic malignancy. This may serve to address the issue of burgeoning healthcare costs and increasing number of sufferers. One potential regimen in service of this alternative is PCA chemoprevention. Here, chemical compounds with cancer preventive efficacy are identified on the basis of their potential in a host of categories: their historical medicinal use, correlation with reduced risk in population studies, non-toxicity, their unique chemical properties, or their role in biological systems. PCA chemopreventive agents are drawn from multiple broad classes of chemicals, themselves further subdivided based on source or potential effect, with most derived from natural products. Many such compounds have shown efficacy, varying from inhibiting deregulated PCA cell signaling, proliferation, epithelial to mesenchymal transition (EMT), invasion, metastasis, tumor growth and angiogenesis and inducing apoptosis. Overall, these chemopreventive agents show great promise in PCA pre-clinical models, though additional work remains to be done in effectively translating these findings into clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.